Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, announces increased production of paracetamol-based medicines for the treatment of fever and pain in children to meet increased market demand. We are in the middle of the children's respiratory season and paracetamol-based medicines are very hard to find or are missing from pharmacies. Therefore, we have mobilised and decided to significantly increase production of Bioflu Baby, a paracetamol-based syrup for treating fever and pain in children. Biofarm has an extensive portfolio of products for children colds and flu, and our two manufacturing facilities have the capacity to adapt quickly to any market need, said Catalin Vicol, Biofarm CEO. Biofarm has always focused on aligning itself with market requirements and patient needs, being a company always oriented towards innovation and facilitating access to modern treatment solutions. In the first ten months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment in terms of number of units sold. The Cold Flu therapeutic area saw the highest growth in the Consumer Healthcare (CHC) category, with products such as Bioflu, Carmol, Bixtonim Xylo and Septosol recording double-digit growth. Biofarm currently has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 200 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory , ORL, cardiovascular ,circulatory, nervous system). With more than 20 representative brands, Biofarm is the market leader in terms of volumes in the reference categories of nine of its brands: Colebil, Triferment, Carbocit, Sennalax, Bixtonim, Carmol, Biofen, Nervocalmin and Cavit. About Biofarm Biofarm® is one of the first Romanian drug and food supplements producers. For 100 years, Biofarm® has stood alongside Romanian specialists in the race to discover the best solutions for maintaining people health. Biofarm® is currently one of the top 10 existing producers on the pharmaceutical market in Romania, a very dynamic and competitive market. Biofarm® has a competitive product portfolio, covering 65 therapeutic areas, and is continuously investing in media, commercial and marketing campaigns to promote its products.
APADOR-CH, one of Romania’s oldest human rights organizations, has called on President Nicușor Dan to clarify how the state intends to combat disinformation without infringing on freedom of expression. In an open letter published on June 14, the organization raised concerns about the president’s recent statement that he would bring the issue of online disinformation […]
Romania’s state-owned passenger railway operator CFR Călători has warned that insufficient public service compensation for 2025, combined with declining revenues, may lead to significant disruptions in rail transport, the company said in a statement issued on June 13. The carrier stated that funding for the upcoming year is expected to fall below 2024 levels, creating […]
Romania's gross external debt (not including the loans contracted by FDI companies from parent groups) increased by 12% y/y or EUR 16.5 billion in 12 months to April 2025, according to data published by the National Bank of Romania. The gross external debt (GED) reached EUR 158.2 billion, equivalent to 44.7% of the country's GDP. […]
Romania’s nominal GDP has reached EUR 354 billion in 2024 and EUR 358 billion in the four quarters to March 2025, nearly tripling from EUR 125 billion in 2009. While often cited as evidence of rapid economic expansion, this 182% increase over 15 years significantly overstates the country’s real economic progress, according to our calculations. […]
Despite positive base effects in April 2025 after net foreign direct investments (FDI) outflows a year earlier, the cumulative net FDI in 12 months to April contracted by 17% y/y to EUR 5.40 billion (EUR 5.45 billion in gross terms), according to data published by the National Bank of Romania on June 13. Notably, the […]
The current account (CA) deficit in the 12 months to April 2025 increased by 46% y/y and reached EUR 33.4 billion, according to data published by the National Bank of Romania (BNR) on June 13. The CA deficit to GDP ratio reached 9.4%, from 7.1% in April 2024 and 8.4% in 2024. All the main […]
